The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque ...

This 2018 review and meta-analysis of other studies totaling over 1,700 people found that the presence of Candida in people with psoriasis was significantly greater than in people without psoriasis.